Alosetron HCl

Alosetron HCl

Alosetron is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS-D) It was patented in 1987 and approved for medical use in 2002. It is currently marketed by Prometheus Laboratories Inc. (San Diego). Alosetron was withdrawn from the market in 2000 owing to the occurrence of serious life-threatening gastrointestinal adverse effects, but was reintroduced in 2002 with availability and use restricted.

Systematic name

5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one;hydrochloride

Brand name(s)

Lotronex

Therapeutic Category

Irritable Bowel Syndrome

Suitable Formulations

Solid

Approvals

USDMF Exclusive for US market

EU-WC

Do you have
a question?
lets Have
a Talk

Nuraychemicals is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2012 by a team with vast experience across the pharmaceutical value chain, the company is on a mission to become the most preferred partner for pharmaceuticals.